Although the FDA or NMPA has approved several PD-1/PD-L1/CTLA-4 inhibitor monotherapies for use in advanced HCC, their efficacy is still limited and is not the treatment of choice (Figure 2). This evidence concerns the gene CD274 and hepatocellular carcinoma.